~~<i id='67C8DC92F8'><strike id='67C8DC92F8'><tt id='67C8DC92F8'><pre id='67C8DC92F8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

author：focus 2025-10-01 21:09:52 - browse：4

Adam's take main illustration — Molly Ferguson/STAT

I was wrong about Geron.

For years, I’ve believed — and declared publicly — that Geron’s effort to develop a blood cancer drug called imetelstat would end in disappointment. The drug was never getting approved, I said.

On Thursday, a group of outside experts convened by the Food and Drug Administration voted 12-2 in imetelstat’s favor, concluding the drug’s benefits outweighed its risks for the treatment of patients with myelodysplastic syndrome. The strong endorsement makes an FDA approval highly likely. The decision is expected on or before June 16.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： A virus, fished out of a lake, may have saved a man’s life

focus

knowledge

entertainment

Wikipedia

AdobeThisarticleisadaptedfromSTAT’sexclusiveanalysisintheSTATReport: “Climaterankings:Howtopdrugcomp

WSS

FDA authorizes Novavax’s updated Covid

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Medicare innovation center doesn’t save money, experts say

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Flu, Covid vaccination rates decline, new survey data show

FDA rejects Alnylam's heart disease treatment over insufficient data

explore

explore

focus

The high cost of giving birth even with insurance

3 questions for the future of Biden's cancer moonshot

Activists slam private health insurers over coverage restrictions

The biotech scorecard for Q4: 16 stock

Cancer drug shortages should be causing more outrage

Phenylephrine and the overlooked value of the placebo effect

In age of alternative facts, a scholarly course on calling out crap

What we owe ALS patients — and why one company fell short

Malaria cases in Florida and Texas: Here’s what you need to know

Colorectal cancer study finds potential in overlooked immune cell

knowledge

FDA rejects Alnylam's heart disease treatment over insufficient data

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Senate panel eyes new effort on drug shortages

Study points to new risk in gene therapy death of Terry Horgan

FDA rejects Alnylam's heart disease treatment over insufficient data

Stop Congress from blocking public access to science

knowledge

knowledge

entertainment

Wikipedia